Dovato (Dolutegravir Sodium/Lamivudine) Patent Expiration, LOE Window & CMS Spending
Dovato (Dolutegravir Sodium/Lamivudine) by GSK: FDA Orange Book core substance LOE 2030-06-08 (last listed 2031-01-24), 0 AB generics, $839.2M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | GSK |
| FDA Application & Pathway | N211994 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2030-06-08 |
| Last Listed Patent or Exclusivity Date | 2031-01-24 |
| Orange Book Patents (*PED Extensions) | 5 patents (2 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $839.2M |
| 2024 Medicare Part D Spend | $541.1M |
| 2024 Medicaid Spend | $298.1M |
| Reported Wholesale Price Change (CA SB 17) | 3 WAC filings (max 17.8% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for GSK across sibling Meru public-data platforms.